Physician profile
Brian Jw Boyd
NPI 1932242302
$127,014.70
in general payments reported to CMS, 2019-2025
46 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,687 · 2020: $1,758 · 2021: $37K · 2022: $26K · 2023: $23K · 2024: $18K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $4,939 · Consulting Fee: $3,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,162.50 |
| Food and Beverage | $4,938.68 |
| Consulting Fee | $3,325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109,202.15 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $7,233.18 | 2019-2025 | |
| Allergan, INC. | $2,387.97 | 2019-2022 | |
| Amgen INC. | $1,055.46 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $881.11 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $876.91 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $813.68 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Lilly USA, LLC | $586.21 | 2019-2025 | Emgality, Reyvow |
| Lundbeck LLC | $396.16 | 2019-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $280.28 | 2019-2023 | Belbuca |
| Stryker Corporation | $272.84 | 2024-2025 | Na, Sonopet Iq, Vsp System, Vsp Cranial |
| Scilex Pharmaceuticals INC. | $241.12 | 2023-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $237.08 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $229.97 | 2019-2021 | |
| Integra Lifesciences Corporation | $209.97 | 2019-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.